Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug4664 | Vielight RX Plus Wiki | 0.50 |
| drug306 | Anakinra plus oSOC Wiki | 0.50 |
| drug4118 | Standard of care therapies Wiki | 0.50 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug5103 | oSOC Wiki | 0.50 |
| drug1381 | Drug: Standard treatment Standard treatment Wiki | 0.50 |
| drug250 | Aerosolized 13 cis retinoic acid plus Inhalation administration by nebulization captopril 25mg Wiki | 0.50 |
| drug4960 | gammaCore® Sapphire (non-invasive vagus nerve stimulator) Wiki | 0.50 |
| drug4959 | gammaCore® (Vagus nerve stimulation) Wiki | 0.50 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D013577 | Syndrome NIH | 0.04 |
| D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.04 |
| D055371 | Acute Lung Injury NIH | 0.04 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There are 4 clinical trials
The main objective of the ANACONDA-COVID-19 trial is to assess the efficacy of Anakinra + optimized Standard of Care (oSOC) as compared to oSOC alone on the condition of patients with COVID-19 infection and worsening respiratory symptoms. Success defined as patient alive and free of invasive mechanical ventilation (IMV) and free of Extracorporeal Membrane Oxygenation (ECMO) at Day 14.
Description: The primary endpoint is treatment success at Day 14, defined as a patient alive and not requiring any of the following: Invasive mechanical ventilation (IMV) or Extracorporeal membrane oxygenation (ECMO).
Measure: Treatment success Time: After 14 days of treatmentDescription: Defined as a patient alive and not requiring any of the following: Invasive mechanical ventilation (IMV) or Extracorporeal membrane oxygenation (ECMO).
Measure: Treatment success Time: After 3 days, 10 days and 28 days of treatmentDescription: 1. Not hospitalized, no limitations on activities 2. Not hospitalized, limitation on activities; 3. Hospitalized, not requiring supplemental oxygen; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, on non-invasive ventilation or high flow oxygen devices;6. Hospitalized, on invasive mechanical ventilation or ECMO;7. Death.
Measure: OMS progression scale (on a 7 point ordinal scale) Time: After 3 days, 10 days, 14 days and 28 days of treatmentDescription: Overall survival
Measure: Overall survival Time: After 3 days, 10 days, 14 days and 28 days of treatmentDescription: Time to ICU admission
Measure: Time to ICU admission Time: Up to 28 daysDescription: Time to ventilatory support : extracorporeal membrane oxygenation (ECMO), invasive mechanical ventilation, non-invasive ventilation, high flow oxygen therapy)
Measure: Time to ventilatory support Time: Up to 28 daysDescription: The National Early Warning Score (NEWS) determines the degree of illness of a patient using six physiological findings and one observation. Score from 0 to 20, 0 mean a worse outcome, 20 mean a better outcome
Measure: Change in National Early Warning Score (NEW)from baseline to Day 3, Day 10, Day 14 and Day 28 Time: After 3 days, 10 days, 14 days and 28 days of treatmentDescription: C-reactive proteine (mg/L)
Measure: Change in inflammatory parameter Time: From baseline to Day 3, Day 10, Day 14 and Day 28Description: ferritin (ng/mL)
Measure: Change in inflammatory parameter Time: From baseline to Day 3, Day 10, Day 14 and Day 28Description: lymphocyte count (G/L)
Measure: Change in inflammatory parameter Time: From baseline to Day 3, Day 10, Day 14 and Day 28Description: fibrinogen (g/l)
Measure: Change in inflammatory parameter Time: From baseline to Day 3, Day 10, Day 14 and Day 28Description: Hospital length of stay
Measure: Hospital length of stay Time: Up to 28 daysDescription: Need for Vasopressors (yes or no)
Measure: ICU parameter Time: Up to 28 daysDescription: Evolution of SpO2/FIO2 ratio (no unit)
Measure: ICU parameter Time: Up to 28 daysDescription: Evolution of PaO2/FiO2 ratio (no unit)
Measure: ICU parameter Time: Up to 28 daysDescription: Occurrence of serious adverse events during the study, including infection (bacterial, parasitic, mycotic and viral infection), septic shock, Ankanira hypersensitivity, hepatic damages (SGOT/SGPT, alkaline phosphatase, gammaGT) and neutropenia (Blood count).
Measure: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 Time: Up to 28 daysDescription: The correlation between several of clinical parameters at inclusion (including level of oxygen requirement (saturation), respiratory rate (per min), temperature (°C)…), biological parameters :including, CRP (mg/L), ferritin (µg/L), LDH (UI/L), lymphocyte count (G/L), eosinophil count (G/L), Ddimers (ng/mM), platelet count (G/L), polymorphonuclear count (G/L)...with the primary end point will be explored.
Measure: Predictors of efficacy of Anakinra Time: After 14 days of treatmentThe purpose of this study is to asses the efficacy of the Gammacore device reducing the need for mechanical ventilation in patients diagnosed of Covid-19
The study is a prospective, randomized, controlled investigation designed for comparison of two groups for the reduction of respiratory distress in a CoViD-19 population, using gammaCore Sapphire (nVNS) plus standard of care (active) vs. standard of care alone (SoC), the control group. The gammaCore® (nVNS) treatments will be used acutely and prophylactically. The active and control groups will be diseased and severity matched. The primary objective is to reduce initiation of mechanical ventilation in patients with CoViD-19 compared to the control group. Secondary objectives are to evaluate cytokine trends/prevent cytokine storms, evaluate supplemental oxygen requirements, decrease mortality of CoViD-19 patients and to delay the onset of mechanical ventilation.
Description: measure the change (in hours) between the control group and treatment group
Measure: change in initiation of mechanical ventilation in patients with CoViD-19 compared to the control group. Time: From the time of randomization until the time of initiation of mechanical ventilation, assessed up to day of discharge or death, whichever occurs first, assessed up to 3 monthsDescription: measure the changes in the serum/plasma concentrations of TH1 and TH2-type cytokines
Measure: evaluate cytokine trends Time: From the time of initial blood draw until the time of final blood draw, assessed up to date of mechanical ventilation, death, or discharge from hospital, whichever occurs first,assessed up to 3 monthsDescription: compare the difference in oxygen requirements (liters/min) between the control group and active group for patients admitted to the hospital for CoViD-19.
Measure: evaluate supplemental oxygen requirements Time: From the time of randomization, assessed up to time of mechanical ventilation, day of discharge or death, whichever occurs first,assessed up to 3 monthsDescription: measure the change (in hours) to death between control group and treatment group
Measure: decrease mortality of CoViD-19 patients Time: From the time or randomization until the date of death from any cause, assessed up to day of discharge or death,assessed up to 3 monthsDescription: measure the change (in hours) to time of mechanical ventilation between control group and treatment group
Measure: delay onset of ventilation Time: From the time of randomization until the time of initiation of mechanical ventilation, assessed up to day of discharge or death, whichever occurs first,assessed up to 3 monthsThe objective of this study is to obtain data on the efficacy of the Vielight RX Plus in decreasing time to recovery of symptoms in subjects with COVID-19. The study will be conducted among COVID-19 positive subjects at home in self-isolation via electronic data collection (EDC). There will be no physical contact between the subjects and the Qualified Investigator (QI) or other study staff. This study aims to demonstrate that the Vielight RX Plus is a useful adjunct to standard of care (SOC). We hypothesize that the Vielight RX Plus will accelerate recovery and reduce viral infection severity.
Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports